Proteomic analysis of human low-density lipoprotein reveals the presence of prenylcysteine lyase, a hydrogen peroxide-generating enzyme

Proteomics

Volumn 9, Issue 5, 2009, Pages 1344-1352

  Banfi, Cristina ^a,b   Brioschi, Maura ^a,b   Barcella, Simona ^a,b   Wait, Robin ^c   Begum, Shajna ^c   Galli, Sabrina ^a,b   Rizzi, Andrea ^a   Tremoli, Elena ^a,b  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Hydrogen peroxide; Lipoprotein; Prefractionation techniques; Prenylcysteine lyase

Indexed keywords

ALDEHYDE; ARYLDIALKYLPHOSPHATASE 1; CYSTEINE; ENZYME; FARNESOL; HIGH DENSITY LIPOPROTEIN; HYDROGEN PEROXIDE; ISOPRENOID; LOW DENSITY LIPOPROTEIN; LYASE; OROSOMUCOID; PRENYLCYSTEINE LYASE; RETINOL BINDING PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; ENZYME SUBSTRATE; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; ISOELECTRIC FOCUSING; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN SECRETION;

ADULT; ATHEROSCLEROSIS; CARBON-SULFUR LYASES; CHEMICAL FRACTIONATION; FARNESOL; FEMALE; HUMANS; HYDROGEN PEROXIDE; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MASS SPECTROMETRY;

EID: 63049113213     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800566     Document Type: Article

References (44)

1. Segrest, J. P., Jackson, R. L., Morrisett, J. D., Gotto, A. M., A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett. 1974, 38, 247-258.
2. Mahley, R. W., Innerarity, T. L., Rall, S. C., Weisgraber, K. H., Plasma lipoproteins: Apolipoprotein structure and function. J. Lipid Res. 1984, 25, 1277-1294.
3. Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M. et al., Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417, 750-754.
4. Chait, A., Han, C. Y., Oram, J. F., Heinecke, J. W., Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: Markers or mediators of cardiovascular disease? J. Lipid Res. 2005, 46, 389-403.
5. Davidsson, P., Hulthe, J., Fagerberg, B., Olsson, B. M. et al., A proteomic study of the apolipoproteins in LDL subclasses in patientswith the metabolic syndrome and type 2 diabetes. J. Lipid Res. 2005, 46, 1999-2006.
6. Lee, S. J., Campos, H., Moye, L. A., Sacks, F. M., LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 853-858.
7. Christoffersen, C., Dahlbäck, B., Nielsen, L. B., Apolipoprotein M: Progress in understanding its regulation and metabolic functions. Scand. J. Clin. Lab. Invest. 2006, 66, 631-637.
8. Zuo, X., Speicher, D. W., Comprehensive analysis of complex proteomes using microscale solution isoelectrofocusing prior to narrow pH range two-dimensional electrophoresis. Proteomics 2002, 2, 58-68.
9. Havel, R. J., Eder, H. A., Bragdon, J. H., The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 1955, 34, 1345-1353.
10. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J., Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
11. Brown, W. V., Levy, R. I., Fredrickson, D. S., Studies of the proteins in human plasma very low density lipoproteins. J. Biol. Chem. 1969, 244, 5687-5694.
12. Wait, R., Gianazza, E., Eberini, I., Sironi, L. et al., Proteins of rat serum, urine, and cerebrospinal fluid: VI. Further protein identifications and interstrain comparison. Electrophoresis 2001, 22, 3043-3052.
13. Banfi, C., Mussoni, L., Risé, P., Cattaneo, M. G. et al., Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res. 1999, 85, 208-217.
14. Tschantz, W. R., Digits, J. A., Pyun, H. J., Coates, R. M. et al., Lysosomal prenylcysteine lyase is a FAD-dependent thioether oxidase. J. Biol. Chem. 2001, 276, 2321-2324.
15. Xu, S., Venge, P., Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 2000, 1482, 298-307.
16. Zhang, L., Tschantz, W. R., Casey, P. J., Isolation and characterization of a prenylcysteine lyase from bovine brain. J. Biol. Chem. 1997, 272, 23354-23359.
17. Zhou, M., Diwu, Z., Panchuk-Voloshina, N., Haugland, R. P., A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: Applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal. Biochem. 1997, 253, 162-168.
18. Digits, J. A., Pyun, H. J., Coates, R. M., Casey, P. J., Stereospecificity and kinetic mechanism of human prenylcysteine lyase, an unusual thioether oxidase. J. Biol. Chem. 2002, 277, 41086-41093.
19. Blanco-Vaca, F., Via, D. P., Yang, C. Y., Massey, J. B. et al., Characterization of disulfide-linked heterodimers containing apolipoprotein D in human plasma lipoproteins. J. Lipid Res. 1992, 33, 1785-1796.
20. Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A. et al., Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117, 746-756.
21. Hochepied, T., Berger, F. G., Baumann, H., Libert, C., Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003, 14, 25-34.
22. Louis, E., Belaiche, J., van Kemseke, C., Franchimont, D. et al., A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur. J. Gastroenterol. Hepatol. 1997, 9, 939-944.
23. Schmidt, M. I., Duncan, B. B., Sharrett, A. R., Lindberg, G. et al., Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999, 353, 1649-1652.
24. Yang, Q., Graham, T. E., Mody, N., Preitner, F. et al., Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436, 356-362.
25. Graham, T. E., Yang, Q., Blüher, M., Hammarstedt, A. et al., Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 2006, 354, 2552-2563.
26. Reaven, G. M., The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr. 2005, 25, 391-406.
27. James, R. W., Deakin, S. P., The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 2004, 37, 1986-1994.
28. Fuhrman, B., Volkova, N., Aviram, M., Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 2005, 180, 55-61.
29. Stan, S., Delvin, E., Lambert, M., Seidman, E. et al., Apo A-IV: An update on regulation and physiologic functions. Biochim. Biophys. Acta 2003, 1631, 177-187.
30. Karlsson, H., Leanderson, P., Tagesson, C., Lindahl, M., Lipoproteomics I: Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5, 551-565.
31. de Silva, H. V., Stuart, W. D., Park, Y. B., Mao, S. J. et al., Purification and characterization of apolipoprotein J. J. Biol. Chem. 1990, 265, 14292-14297.
32. Trougakos, I. P., Gonos, E. S., Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic. Res. 2006, 40, 1324-1334.
33. Polz, E., Kostner, G. M., The binding of beta 2-glycoprotein-I to human serum lipoproteins: Distribution among density fractions. FEBS Lett. 1979, 102, 183-186.
34. Wierzbicki, A. S., Lipoproteins: From A to B and maybe C-III. Int. J. Clin. Pract. 2008, 62, 674-676.
35. Mehdi, H., Aston, C. E., Sanghera, D. K., Hamman, R. F. et al., Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations. Hum. Genet. 1999, 105, 63-71.
36. Mancone, C., Amicone, L., Fimia, G. M., Bravo, E. et al., Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOF. Proteomics 2007, 7, 143-154.
37. Tschantz, W. R., Zhang, L., Casey, P. J., Cloning, expression, and cellular localization of a human prenylcysteine lyase. J. Biol. Chem. 1999, 274, 35802-35808.
38. Glomset, J. A., Gelb, M. H., Farnsworth, C. C., Prenyl proteins in eukaryotic cells: A new type of membrane anchor. Trends. Biochem. Sci. 1990, 15, 139-142.
39. Zhang, F. L., Casey, P. J., Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 1996, 65, 241-269.
40. Casey, P. J., Solski, P. A, Der, C. J., Buss, J. E., p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA 1989, 86, 8323-8327.
41. Dekant, W., Vamvakas, S., Anders, M. W., Bioactivation of nephrotoxic haloalkenes by glutathione conjugation: Formation of toxic and mutagenic intermediates by cysteine conjugate beta-lyase. Drug Metab. Rev. 1989, 20, 43-83.
42. Cashman, J. R., Olsen, L. D., Bornheim, L. M., Enantioselective S-oxygenation by flavin-containing and cytochrome P-450 monooxygenases. Chem. Res. Toxicol. 1990, 3, 344-349.
43. Sausen, P. J., Elfarra, A. A., Cysteine conjugate S-oxidase. Characterization of a novel enzymatic activity in rat hepatic and renal microsomes. J. Biol. Chem. 1990, 265, 6139-6145.
44. Park, S. B., Howald, W. N., Cashman, J. R., S-oxidative cleavage of farnesylcysteine and farnesylcysteine methyl ester by the flavin-containing monooxygenase. Chem. Res. Toxicol. 1994, 7, 191-198.